Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CAPR 
Capricor Therapeutics Inc (CAPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: CAPR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20.6
1 Year Target Price $20.6
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 41.82% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 306.30M USD | Price to earnings Ratio - | 1Y Target Price 20.6 |
Price to earnings Ratio - | 1Y Target Price 20.6 | ||
Volume (30-day avg) 8 | Beta 0.69 | 52 Weeks Range 5.68 - 22.90 | Updated Date 10/15/2025 |
52 Weeks Range 5.68 - 22.90 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -548.16% |
Management Effectiveness
Return on Assets (TTM) -53.4% | Return on Equity (TTM) -120.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 242607717 | Price to Sales(TTM) 22.87 |
Enterprise Value 242607717 | Price to Sales(TTM) 22.87 | ||
Enterprise Value to Revenue 18.12 | Enterprise Value to EBITDA -2.73 | Shares Outstanding 45716975 | Shares Floating 40185221 |
Shares Outstanding 45716975 | Shares Floating 40185221 | ||
Percent Insiders 16.79 | Percent Institutions 30.69 |
Upturn AI SWOT
Capricor Therapeutics Inc
Company Overview
History and Background
Capricor Therapeutics, Inc. was founded in 2005. It's a biotechnology company focused on developing and commercializing cell and exosome-based therapeutics for preventing and treating diseases.
Core Business Areas
- Exosome-Based Therapeutics: Develops engineered exosomes to deliver RNA, proteins, and small molecules to targeted tissues. Leading program is for Duchenne Muscular Dystrophy (DMD).
- Cell-Based Therapeutics: Development of cell therapies for cardiovascular and other inflammatory diseases.
Leadership and Structure
Linda Marbu00e1n, Ph.D. serves as CEO. The company has a standard corporate structure with departments focusing on research, development, clinical trials, and operations.
Top Products and Market Share
Key Offerings
- CAP-1002 (Cell Therapy): An investigational cell therapy for Duchenne Muscular Dystrophy (DMD) and other cardiac indications. It has received Orphan Drug Designation from the FDA. No current market share. Competitors developing therapies for DMD include Sarepta Therapeutics, PTC Therapeutics, and Solid Biosciences.
- Exosome Platform: Capricor is developing an exosome-based technology platform. No specific product revenue associated with this. Competitors in exosome therapeutics include Codiak BioSciences (bankrupt), Evox Therapeutics and PureTech Health.
Market Dynamics
Industry Overview
The biopharmaceutical industry is driven by innovation, with a focus on developing treatments for unmet medical needs. There is a growing interest in cell and exosome therapies as potential treatments for a variety of diseases.
Positioning
Capricor is positioned as a company specializing in cell and exosome-based therapies. Its competitive advantage lies in its proprietary technology and focus on targeted therapies.
Total Addressable Market (TAM)
The TAM for DMD therapies is estimated to be in the billions of dollars. Capricor's positioning hinges on successfully navigating clinical trials and gaining regulatory approval for CAP-1002 and its exosome products.
Upturn SWOT Analysis
Strengths
- Proprietary cell and exosome technology platform
- Orphan Drug Designation for CAP-1002
- Experienced leadership team
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited financial resources
- High regulatory hurdles
Opportunities
- Expanding applications of cell and exosome therapies
- Partnerships with larger pharmaceutical companies
- Potential for breakthrough therapies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from larger pharmaceutical companies
Competitors and Market Share
Key Competitors
- SRPT
- PTCT
- BMY
Competitive Landscape
Capricor faces competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its specialized technology and focus on targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by progress in clinical trials and partnerships.
Future Projections: Future growth depends on the successful development and commercialization of its cell and exosome therapies. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for CAP-1002 and expanding its exosome platform.
Summary
Capricor Therapeutics is a high-risk, high-reward biotechnology company. Its strengths lie in its proprietary technology and focus on cell and exosome therapies. Success is contingent on favorable clinical trial outcomes and obtaining regulatory approvals, while threats include clinical failures and strong competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings, Corporate Website, Industry Reports, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may be subject to change. Investment decisions should be made based on individual risk tolerance and financial circumstances.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Capricor Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2007-02-13 | Co-Founder, President, CEO & Director Dr. Linda Marbán Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 160 | Website https://www.capricor.com |
Full time employees 160 | Website https://www.capricor.com | ||
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.